NASDAQ:DMAC DiaMedica Therapeutics Q1 2023 Earnings Report $1.22 +0.11 (+9.91%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.22 0.00 (-0.41%) As of 04/17/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Fractyl Health EPS ResultsActual EPS-$0.20Consensus EPS -$0.16Beat/MissMissed by -$0.04One Year Ago EPSN/AFractyl Health Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFractyl Health Announcement DetailsQuarterQ1 2023Date5/15/2023TimeN/AConference Call DateTuesday, May 16, 2023Conference Call Time8:00AM ETUpcoming EarningsFractyl Health's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Fractyl Health Q1 2023 Earnings Call TranscriptProvided by QuartrMay 16, 2023 ShareLink copied to clipboard.There are 7 speakers on the call. Operator00:00:00Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2023 www.diamedica.com in the Investor Relations section. Proceeds with its remarks. Please note that the company will be making forward looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results appears in the section entitled Cautionary Note regarding forward looking statements in the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10 ks and subsequent quarterly report on Form 10 Q. Operator00:01:06DiaMedica's SEC filings are available at the SEC's website, www.sec.gov and on its website. Please also note that any comments made on today's call speak only as of today, May 16, 2023 and may no longer be accurate at the time of any replay or transcript rereading. Dia Medica disclaims any duty to update its forward looking statements. Following the prepared remarks, we will open the phone lines for questions. I would now like to introduce your host for today's call, Mr. Operator00:01:45Rick Pauls, DiaMedica's President and Executive Officer. Mr. Pauls, you may begin, sir. Speaker 100:01:53Thank you, operator. Hello, everyone, and welcome I am joined this morning with Doctor. Kirsten Grusz, our Chief Medical Officer and Scott Kellen, our Chief Financial Officer. I am happy to report this morning that our complete response requesting the lifting of our clinical hold is being finalized as we speak and we plan to submit to the FDA this week. Much hard work has been performed to get us here. Speaker 100:02:17The FDA requested a new study was completed in April. This was performed at an independent laboratory and consisted of 2 parts. Part 1 simulated actual use in the hospital of drug being administered And Part 2 evaluated worst case scenarios such as varying storage durations, temperature and light exposure. We believe that the data from Part 1 confirmed our conclusions that the effects of the change in the IV bag material was the cause of the hypotensive events leading to our halting of enrollment in the study. Results from Part 2 of the INU study were substantially consistent with Part 1, which means that there were Likely be no new special handling instructions required for the IV administration of DM199. Speaker 100:03:03I would also point out that Part 1 results were consistent with the results of the IV bag testing we completed in the fall of last year, where we proposed revising the IV dose to 0.5 micrograms per kg to match our Phase 2 stroke trial IV dosing levels. We hope that this will contribute to a favorable decision by the FDA. And just to remind everyone, there are no proposed changes to the ensuing 3 weeks subcutaneous dosing under the study protocol. I'm also very pleased to report that we have recently completed a Phase 1c in healthy volunteers trial. Even though the FDA did not request or suggest human testing, we plan and initiated a Phase 1c open label single ascending dose study of DM199 This study was conducted in Australia. Speaker 100:04:03The results is confirmed to us with human data that a proposed revised IV dose of DM199 of 0.5 micrograms per kg would be generally safe, well tolerated and achieved a blood concentration level that reached the desired therapeutic range as seen in our prior Phase 2 acute ischemic stroke trial. The results from this Phase 1c study give us further confidence that a proposed DM199 IV dose revision to 0.5 micrograms per kg for REMEDY-two will minimize the risk for clinically significant hypertension and reach the targeted range. These results will be included as additional supporting data in our clinical hold response. We also believe that this study and the resulting data demonstrate our commitment to patient safety and provide greater comfort for our prior and new principal investigators and study sites to engage in and support the REMEDY-two trial. As a result of all this work, we are optimistic that we have fully identified the cause for last year's unexpected hypotensive events and we'll be providing the FDA with adequate data to support our analysis of the cause of the prior comprehensive events. Speaker 100:05:15We believe the results of the Phase 1c study further support our proposed revision to the IV dose of 0.5 micrograms per kg and demonstrate the safety and tolerability of DM199. All in, we are cautiously optimistic that this will allow the FDA to lift the clinical hold. With the expansion of our team this past year, I'm confident that we have the right team in place to execute the REMEDY-two trial, which we believe will be a pivotal trial. Once we hear back from the FDA and if the response is positive, we will provide an update on the next steps and expected timing for relaunching the REMEDY-two trial. We have also recently expanded our management team with the addition of David Wombeck as our Chief Business conference call. Speaker 100:05:58Dave brings over 15 years of relevant life sciences, capital markets, M and A and Investor Relations experience to DiaMedica. He was actually the lead banker on our 2018 initial public offering on NASDAQ and has been one of my most reliable and trusted outside advisors over the past 5 years. And as well, he has an extensive understanding of our DM199 programs. He also brings key relationships across the biotech and investment communities. David is committed to advancing DM199 as you can tell with his recent purchase of $750,000 of DiaMedica's common stock. Speaker 100:06:34We're grateful Speaker 200:06:35to have him part of our team. I would like to now turn the call to Scott Kellen to review the financial highlights. Thanks, Rick, and good morning, everyone. As Rick mentioned, we announced our Q1 2023 financial results and filed our quarterly report on Form 10 Q yesterday afternoon. These Our combined cash and investments totaled $28,700,000 down from $33,500,000 as of the end of 2022. Speaker 200:07:14Our Q1 2023 cash usage was $5,100,000 compared to $3,900,000 in the prior year period. The increase in our cash usage was due primarily to the end use and the Phase 1c studies. We believe that our current cash will support the clinical development of DM199 and our operations into the Q4 of next year. Our research and development expenses increased to $3,600,000 for the 3 months ended March 31, 2023, up $1,600,000 from $2,000,000 for the 1st 3 months ended March 31, 2022. The increased costs were driven by a number of factors, including increased manufacturing and process development costs, costs for the end use and the Phase 1c studies and increased personnel costs associated with the expansion of the clinical team. Speaker 200:08:15These increases were partially offset by decreased costs incurred in the Phase twothree REMEDY 2 stroke trial due to the clinical hold. Our general and administrative expenses were $1,900,000 for the 3 months ended March 31, 2020 up from $1,600,000 for the same period in the prior year. The increase was primarily due to recruiting costs incurred in conjunction with the expansion of the company's team and increased legal fees incurred in connection with the company's lawsuit against PRA Netherlands. Speaking of which, let me provide a quick update on our ongoing lawsuit against PRA Netherlands, which as of July 1, 2021 was acquired by Icon Plc. Last month, The Netherland Commercial Court issued its ruling on the matter of our ownership of the study data and records from the trial that PRAICON ran for us in 2013 2014. Speaker 200:09:20In that ruling, the court declared that DiaMedica was the rightful owner of the study records, both paper and electronic as stipulated in the original study agreement. The court ordered PRA slash Icon to allow and tolerate that DiaMedica exercise its right as owner of documents and to cooperate with the surrender of both the physical documents and the digital data. The court further ruled that PRAICON had no legal basis for withholding the study documents. After all these years, that ruling was quite the vindication. We now look forward to obtaining the records and conducting a proper audit of the study and to evaluate the inconsistent messaging from PRA. Speaker 200:10:11We are currently taking steps to enforce the court's ruling and to get access to the study documents. PRA however does have a right to appeal this decision. This right lasts until mid July of this year. At that We'll be able to provide some clarity on the timing for the next steps through the Netherlands legal system. So thank you. Speaker 200:10:34And with With that, let me turn the call back over to Rick. Speaker 300:10:38Thanks, Scott. With that, Speaker 100:10:39we'd like to open the call for questions. Operator, if you could please introduce the first analyst. Speaker 400:11:09Conference Call. And our first question comes from Thomas Flaten of Lake Street Capital. Your line is open. Speaker 500:11:17Thanks. Good morning, guys. And I appreciate you taking the questions. Rick, I was curious and maybe I misunderstood from the last call That the Part 1C was kind of a back pocket data set that you could use in the event that FDA had ongoing questions, but it's now going to be submitted as part of your formal response to with the INU study. I was just curious if you could comment on that. Speaker 500:11:38Was it more just that the timing worked out or was there a change in strategy there? Speaker 100:11:42Comp? No, really good question. So it really was a question of timing. And so we were preparing to submit Our complete response in April, the end of April, with combining both the Part 1 and Part 2 of the end use. And then we realized that the Phase 1 seen healthy volunteers was moving along very quickly. Speaker 100:12:07And so recognizing that in just a couple of more weeks, we could actually do a complete response that would actually include human data. And encouragingly, that human data now supports the in use data and also supports the IV BAG study we did last fall. So we think overall, the combination of the INU study, the Phase 1C data, we believe provides a very compelling basis for the FDA to allow us to resume the trial. Speaker 500:12:36And thanks for that. And just Looking back a bit, when you guys conceived of the 1 microgram per kilogram dose, I'm assuming that was a translation from the either the porcine or the the dose. I was just curious what you guys have maybe gone back on a postmortem basis to understand, should you have been at 1 microgram in the 1st place? Comp? I'm just maybe some post mortem thoughts on that. Speaker 100:13:10Yes. So if you go back, so we initially did a Phase 1 trial in healthy subjects that look to match the PK profile of the IV dose of our drug compared to the human urinary form that's being used today in China. And at the time we'd use the polyofran bag and we're using that bag, We came up with a 1 microgram per kg dose levels. Fast forward, that was the same bag that we used for our Phase 2 that we had the Phase two results. And then when we progressed and moved to our Phase twothree that initiated last year, We pivoted to a PVC bag and that's where we had the 3 serious adverse events of large drops in blood pressure. Speaker 100:14:00Last summer, we went back and looked at what changed from the Phase 2 to the Phase twothree. And that's where we recognized that The really only thing that we could determine was changing the bags. Did additional work, both last summer and then further with the in use. And what we now realize is that the polyoferm bag that effectively half the drug was sticking. And so effectively the 1 microgram per kg using the PVC bag was giving patients twice the dose. Speaker 100:14:31So that we thought that they were getting. So with this new in use study in the Phase 1c, we were able to basically match up to a similar PK profile using the PVC bag Speaker 400:14:46as we did with the Speaker 500:14:47previous Got it. Thanks, Rick. Speaker 400:14:55And our next question comes from Alex Nowak from Craig Hallum. Your line is open. Speaker 300:15:03All right. Great. Good morning, everyone. So to continue to ask Tom's questions there, I think that the work that you've done here is really interesting To go back and just confirm the dose levels, would you plan on publishing that work just showing all the steps you took from root cause identification, how you ended up solving it, the studies that you've done either published this at a conference or published an abstract somewhere, just so I think we can add some more hard supports heart evidence around the kind of changes in the study design? Speaker 100:15:36Yes. It's something that we're talking about. I guess we're not going to commit to it, but it will be something that's important. And in particular for the principal investigators at these sites. So if we can give greater clarity, we'll be looking at how to get that data out. Speaker 100:15:51So it is very clearly we have identified what happened And why we believe that we'll be able to avoid these events for the most part going forward. Speaker 300:16:01Okay. No, that's good. Anything from the in use study of the Phase 1c data that's going to make the FDA go, Okay, great. Thanks for providing this. But have you considered XYZ? Speaker 300:16:12What could we be still surprised by the FDA's response here? Speaker 100:16:17Comp? We've done what we think has been a very extensive review. We've used a number of different outside consultants as well to help us to review everything. We thought we had the data with the in use and then we feel by taking this even further in running a study in humans That I mentioned on the prepared remarks was not required or indicated or alluded to by the FDA. We think this is ideally this will give them more comfort In terms of we're doing everything we can regarding patient safety. Speaker 100:16:51Other aspect to it, we've also done some revisions to the protocol. And so in particular, we'll be starting the infusion for the first 15 minutes, slow. And if there are any signs of drop some blood pressure that are significant then the sites can dose these patients over a few hours. We think that'll be important. And then we also are doing a 24 hour washout if a patient was previously on an ACE inhibitor. Speaker 100:17:18So these three patients were all on ACE inhibitors that had the serious adverse event. And so we know there is an interaction with ACE inhibitors in terms of the mechanism of action. So So we think these additional precautionary steps that Kirsten and the clinical team have added, I think will provide more comfort as well in terms of prevention. Until we get the feedback from the FDA, we don't know, but we believe we've answered everything. There's some additional questions that the FDA had also asked regards to tripsin and Our assay and they've already responded that they thought that the work we've done has been acceptable. Speaker 100:17:56So we'll plan to file this week and then the FDA will have up to 30 days to get us a response. Speaker 300:18:03Okay. No, that's great. And then maybe just two quick questions. One was, I think you mentioned in the prepared remarks, there was new principal investigators in the study. Can you just elaborate on that? Speaker 300:18:13And then just remind us on the PRA lawsuit, what study was PRA conducting going back almost 10 years now. What data is there that you'd like to get or you're going to get and what could be helpful in that data for for the ongoing development of DM199? Speaker 100:18:32Yes. So the first part is my prepared remarks in reference We had 15 sites that we had under contract and on clinicaltrials dot gov. And then we have numerous others that we've had different layers of interaction that as soon as we get the whole feedback from the FDA and coming off, We'll be full steam on getting as many of these sites up as quickly as we can. And then let Scott take the PRA question. Speaker 200:18:59Hi, Alex. Yes, good question on PRA. It's been a while. They were doing the original first in man work. So the original dose tolerance studies, a number of single and multiple ascending dose studies that culminated in a small proof of concept study for type 2 diabetes. Speaker 200:19:19And the lawsuit issues revolve around that proof of concept study where Their representations as to what we would expect, what we could expect from the outcome of that study didn't match what they initially reported as the outcome and then they refused to allow us access to perform a proper audit of the study to truly understand what actually happened. So we're waiting to see the data to understand whether or not we have a signal for the overall development. But we'll wait until we see what those results are before we form an opinion on whether or not we should be looking harder Back at type 2 diabetes. Speaker 300:20:12Yes, absolutely. It will be great to see that data. All right. Appreciate the update. Thank you. Speaker 400:20:28Conference. And we have a question from Francois Bisbo from Conference Call Oppenheimer. Your line is open. Speaker 600:20:39Hi, this is Dan. Sorry about that. Hi, this is Dan on for Frank. Thanks for taking my question. Regarding the P1C, You mentioned the 0.5 microgram per kilogram achieved the exposure levels similar to REMEDY-one. Speaker 600:20:55Of course, these are healthy volunteers, but Were there any PD parameters that were part of the data collected? Are you if you're able to share at this time if there was any dose response in the PKPD parameters in across the in across the 3 doses, any additional granularity you can share at this time on the P1C? Thanks. Speaker 100:21:24I think we've been having some troubles here with We lost Kirsten. Lost her here. Dan, no, I mean, this was these patients were healthy subjects. And I'll point out that the study design was quite similar to our Phase 1 trial we did in healthy subjects before launching our Phase 2 study for stroke. Speaker 600:21:48Thanks. Thanks for taking my questions. Speaker 500:21:53Thanks, Dan. Speaker 400:21:54Thank you. And seeing no further questions in queue at this time, I'll turn the call back over to our host. Speaker 100:22:02All right. Again, we'd like to thank everyone for joining us this morning and for your continued support. Our goal is to bring this important treatment to stroke patients asRead morePowered by Conference Call Audio Live Call not available Earnings Conference CallFractyl Health Q1 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Fractyl Health Earnings HeadlinesFractyl Health (NASDAQ:GUTS) Coverage Initiated by Analysts at Canaccord Genuity GroupApril 18 at 3:19 AM | americanbankingnews.comCanaccord Genuity Initiates Coverage of Fractyl Health (GUTS) with Buy RecommendationApril 16 at 5:24 AM | msn.comClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...April 18, 2025 | American Alternative (Ad)Comparing Fractyl Health (NASDAQ:GUTS) and Glaukos (NYSE:GKOS)April 12, 2025 | americanbankingnews.comFractyl Health reports early data from REVEAL-1 cohort of REMAIN-1 studyApril 2, 2025 | markets.businessinsider.comFractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025April 2, 2025 | insidermonkey.comSee More Fractyl Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fractyl Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fractyl Health and other key companies, straight to your email. Email Address About Fractyl HealthFractyl Health (NASDAQ:GUTS), a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.View Fractyl Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 7 speakers on the call. Operator00:00:00Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2023 www.diamedica.com in the Investor Relations section. Proceeds with its remarks. Please note that the company will be making forward looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results appears in the section entitled Cautionary Note regarding forward looking statements in the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10 ks and subsequent quarterly report on Form 10 Q. Operator00:01:06DiaMedica's SEC filings are available at the SEC's website, www.sec.gov and on its website. Please also note that any comments made on today's call speak only as of today, May 16, 2023 and may no longer be accurate at the time of any replay or transcript rereading. Dia Medica disclaims any duty to update its forward looking statements. Following the prepared remarks, we will open the phone lines for questions. I would now like to introduce your host for today's call, Mr. Operator00:01:45Rick Pauls, DiaMedica's President and Executive Officer. Mr. Pauls, you may begin, sir. Speaker 100:01:53Thank you, operator. Hello, everyone, and welcome I am joined this morning with Doctor. Kirsten Grusz, our Chief Medical Officer and Scott Kellen, our Chief Financial Officer. I am happy to report this morning that our complete response requesting the lifting of our clinical hold is being finalized as we speak and we plan to submit to the FDA this week. Much hard work has been performed to get us here. Speaker 100:02:17The FDA requested a new study was completed in April. This was performed at an independent laboratory and consisted of 2 parts. Part 1 simulated actual use in the hospital of drug being administered And Part 2 evaluated worst case scenarios such as varying storage durations, temperature and light exposure. We believe that the data from Part 1 confirmed our conclusions that the effects of the change in the IV bag material was the cause of the hypotensive events leading to our halting of enrollment in the study. Results from Part 2 of the INU study were substantially consistent with Part 1, which means that there were Likely be no new special handling instructions required for the IV administration of DM199. Speaker 100:03:03I would also point out that Part 1 results were consistent with the results of the IV bag testing we completed in the fall of last year, where we proposed revising the IV dose to 0.5 micrograms per kg to match our Phase 2 stroke trial IV dosing levels. We hope that this will contribute to a favorable decision by the FDA. And just to remind everyone, there are no proposed changes to the ensuing 3 weeks subcutaneous dosing under the study protocol. I'm also very pleased to report that we have recently completed a Phase 1c in healthy volunteers trial. Even though the FDA did not request or suggest human testing, we plan and initiated a Phase 1c open label single ascending dose study of DM199 This study was conducted in Australia. Speaker 100:04:03The results is confirmed to us with human data that a proposed revised IV dose of DM199 of 0.5 micrograms per kg would be generally safe, well tolerated and achieved a blood concentration level that reached the desired therapeutic range as seen in our prior Phase 2 acute ischemic stroke trial. The results from this Phase 1c study give us further confidence that a proposed DM199 IV dose revision to 0.5 micrograms per kg for REMEDY-two will minimize the risk for clinically significant hypertension and reach the targeted range. These results will be included as additional supporting data in our clinical hold response. We also believe that this study and the resulting data demonstrate our commitment to patient safety and provide greater comfort for our prior and new principal investigators and study sites to engage in and support the REMEDY-two trial. As a result of all this work, we are optimistic that we have fully identified the cause for last year's unexpected hypotensive events and we'll be providing the FDA with adequate data to support our analysis of the cause of the prior comprehensive events. Speaker 100:05:15We believe the results of the Phase 1c study further support our proposed revision to the IV dose of 0.5 micrograms per kg and demonstrate the safety and tolerability of DM199. All in, we are cautiously optimistic that this will allow the FDA to lift the clinical hold. With the expansion of our team this past year, I'm confident that we have the right team in place to execute the REMEDY-two trial, which we believe will be a pivotal trial. Once we hear back from the FDA and if the response is positive, we will provide an update on the next steps and expected timing for relaunching the REMEDY-two trial. We have also recently expanded our management team with the addition of David Wombeck as our Chief Business conference call. Speaker 100:05:58Dave brings over 15 years of relevant life sciences, capital markets, M and A and Investor Relations experience to DiaMedica. He was actually the lead banker on our 2018 initial public offering on NASDAQ and has been one of my most reliable and trusted outside advisors over the past 5 years. And as well, he has an extensive understanding of our DM199 programs. He also brings key relationships across the biotech and investment communities. David is committed to advancing DM199 as you can tell with his recent purchase of $750,000 of DiaMedica's common stock. Speaker 100:06:34We're grateful Speaker 200:06:35to have him part of our team. I would like to now turn the call to Scott Kellen to review the financial highlights. Thanks, Rick, and good morning, everyone. As Rick mentioned, we announced our Q1 2023 financial results and filed our quarterly report on Form 10 Q yesterday afternoon. These Our combined cash and investments totaled $28,700,000 down from $33,500,000 as of the end of 2022. Speaker 200:07:14Our Q1 2023 cash usage was $5,100,000 compared to $3,900,000 in the prior year period. The increase in our cash usage was due primarily to the end use and the Phase 1c studies. We believe that our current cash will support the clinical development of DM199 and our operations into the Q4 of next year. Our research and development expenses increased to $3,600,000 for the 3 months ended March 31, 2023, up $1,600,000 from $2,000,000 for the 1st 3 months ended March 31, 2022. The increased costs were driven by a number of factors, including increased manufacturing and process development costs, costs for the end use and the Phase 1c studies and increased personnel costs associated with the expansion of the clinical team. Speaker 200:08:15These increases were partially offset by decreased costs incurred in the Phase twothree REMEDY 2 stroke trial due to the clinical hold. Our general and administrative expenses were $1,900,000 for the 3 months ended March 31, 2020 up from $1,600,000 for the same period in the prior year. The increase was primarily due to recruiting costs incurred in conjunction with the expansion of the company's team and increased legal fees incurred in connection with the company's lawsuit against PRA Netherlands. Speaking of which, let me provide a quick update on our ongoing lawsuit against PRA Netherlands, which as of July 1, 2021 was acquired by Icon Plc. Last month, The Netherland Commercial Court issued its ruling on the matter of our ownership of the study data and records from the trial that PRAICON ran for us in 2013 2014. Speaker 200:09:20In that ruling, the court declared that DiaMedica was the rightful owner of the study records, both paper and electronic as stipulated in the original study agreement. The court ordered PRA slash Icon to allow and tolerate that DiaMedica exercise its right as owner of documents and to cooperate with the surrender of both the physical documents and the digital data. The court further ruled that PRAICON had no legal basis for withholding the study documents. After all these years, that ruling was quite the vindication. We now look forward to obtaining the records and conducting a proper audit of the study and to evaluate the inconsistent messaging from PRA. Speaker 200:10:11We are currently taking steps to enforce the court's ruling and to get access to the study documents. PRA however does have a right to appeal this decision. This right lasts until mid July of this year. At that We'll be able to provide some clarity on the timing for the next steps through the Netherlands legal system. So thank you. Speaker 200:10:34And with With that, let me turn the call back over to Rick. Speaker 300:10:38Thanks, Scott. With that, Speaker 100:10:39we'd like to open the call for questions. Operator, if you could please introduce the first analyst. Speaker 400:11:09Conference Call. And our first question comes from Thomas Flaten of Lake Street Capital. Your line is open. Speaker 500:11:17Thanks. Good morning, guys. And I appreciate you taking the questions. Rick, I was curious and maybe I misunderstood from the last call That the Part 1C was kind of a back pocket data set that you could use in the event that FDA had ongoing questions, but it's now going to be submitted as part of your formal response to with the INU study. I was just curious if you could comment on that. Speaker 500:11:38Was it more just that the timing worked out or was there a change in strategy there? Speaker 100:11:42Comp? No, really good question. So it really was a question of timing. And so we were preparing to submit Our complete response in April, the end of April, with combining both the Part 1 and Part 2 of the end use. And then we realized that the Phase 1 seen healthy volunteers was moving along very quickly. Speaker 100:12:07And so recognizing that in just a couple of more weeks, we could actually do a complete response that would actually include human data. And encouragingly, that human data now supports the in use data and also supports the IV BAG study we did last fall. So we think overall, the combination of the INU study, the Phase 1C data, we believe provides a very compelling basis for the FDA to allow us to resume the trial. Speaker 500:12:36And thanks for that. And just Looking back a bit, when you guys conceived of the 1 microgram per kilogram dose, I'm assuming that was a translation from the either the porcine or the the dose. I was just curious what you guys have maybe gone back on a postmortem basis to understand, should you have been at 1 microgram in the 1st place? Comp? I'm just maybe some post mortem thoughts on that. Speaker 100:13:10Yes. So if you go back, so we initially did a Phase 1 trial in healthy subjects that look to match the PK profile of the IV dose of our drug compared to the human urinary form that's being used today in China. And at the time we'd use the polyofran bag and we're using that bag, We came up with a 1 microgram per kg dose levels. Fast forward, that was the same bag that we used for our Phase 2 that we had the Phase two results. And then when we progressed and moved to our Phase twothree that initiated last year, We pivoted to a PVC bag and that's where we had the 3 serious adverse events of large drops in blood pressure. Speaker 100:14:00Last summer, we went back and looked at what changed from the Phase 2 to the Phase twothree. And that's where we recognized that The really only thing that we could determine was changing the bags. Did additional work, both last summer and then further with the in use. And what we now realize is that the polyoferm bag that effectively half the drug was sticking. And so effectively the 1 microgram per kg using the PVC bag was giving patients twice the dose. Speaker 100:14:31So that we thought that they were getting. So with this new in use study in the Phase 1c, we were able to basically match up to a similar PK profile using the PVC bag Speaker 400:14:46as we did with the Speaker 500:14:47previous Got it. Thanks, Rick. Speaker 400:14:55And our next question comes from Alex Nowak from Craig Hallum. Your line is open. Speaker 300:15:03All right. Great. Good morning, everyone. So to continue to ask Tom's questions there, I think that the work that you've done here is really interesting To go back and just confirm the dose levels, would you plan on publishing that work just showing all the steps you took from root cause identification, how you ended up solving it, the studies that you've done either published this at a conference or published an abstract somewhere, just so I think we can add some more hard supports heart evidence around the kind of changes in the study design? Speaker 100:15:36Yes. It's something that we're talking about. I guess we're not going to commit to it, but it will be something that's important. And in particular for the principal investigators at these sites. So if we can give greater clarity, we'll be looking at how to get that data out. Speaker 100:15:51So it is very clearly we have identified what happened And why we believe that we'll be able to avoid these events for the most part going forward. Speaker 300:16:01Okay. No, that's good. Anything from the in use study of the Phase 1c data that's going to make the FDA go, Okay, great. Thanks for providing this. But have you considered XYZ? Speaker 300:16:12What could we be still surprised by the FDA's response here? Speaker 100:16:17Comp? We've done what we think has been a very extensive review. We've used a number of different outside consultants as well to help us to review everything. We thought we had the data with the in use and then we feel by taking this even further in running a study in humans That I mentioned on the prepared remarks was not required or indicated or alluded to by the FDA. We think this is ideally this will give them more comfort In terms of we're doing everything we can regarding patient safety. Speaker 100:16:51Other aspect to it, we've also done some revisions to the protocol. And so in particular, we'll be starting the infusion for the first 15 minutes, slow. And if there are any signs of drop some blood pressure that are significant then the sites can dose these patients over a few hours. We think that'll be important. And then we also are doing a 24 hour washout if a patient was previously on an ACE inhibitor. Speaker 100:17:18So these three patients were all on ACE inhibitors that had the serious adverse event. And so we know there is an interaction with ACE inhibitors in terms of the mechanism of action. So So we think these additional precautionary steps that Kirsten and the clinical team have added, I think will provide more comfort as well in terms of prevention. Until we get the feedback from the FDA, we don't know, but we believe we've answered everything. There's some additional questions that the FDA had also asked regards to tripsin and Our assay and they've already responded that they thought that the work we've done has been acceptable. Speaker 100:17:56So we'll plan to file this week and then the FDA will have up to 30 days to get us a response. Speaker 300:18:03Okay. No, that's great. And then maybe just two quick questions. One was, I think you mentioned in the prepared remarks, there was new principal investigators in the study. Can you just elaborate on that? Speaker 300:18:13And then just remind us on the PRA lawsuit, what study was PRA conducting going back almost 10 years now. What data is there that you'd like to get or you're going to get and what could be helpful in that data for for the ongoing development of DM199? Speaker 100:18:32Yes. So the first part is my prepared remarks in reference We had 15 sites that we had under contract and on clinicaltrials dot gov. And then we have numerous others that we've had different layers of interaction that as soon as we get the whole feedback from the FDA and coming off, We'll be full steam on getting as many of these sites up as quickly as we can. And then let Scott take the PRA question. Speaker 200:18:59Hi, Alex. Yes, good question on PRA. It's been a while. They were doing the original first in man work. So the original dose tolerance studies, a number of single and multiple ascending dose studies that culminated in a small proof of concept study for type 2 diabetes. Speaker 200:19:19And the lawsuit issues revolve around that proof of concept study where Their representations as to what we would expect, what we could expect from the outcome of that study didn't match what they initially reported as the outcome and then they refused to allow us access to perform a proper audit of the study to truly understand what actually happened. So we're waiting to see the data to understand whether or not we have a signal for the overall development. But we'll wait until we see what those results are before we form an opinion on whether or not we should be looking harder Back at type 2 diabetes. Speaker 300:20:12Yes, absolutely. It will be great to see that data. All right. Appreciate the update. Thank you. Speaker 400:20:28Conference. And we have a question from Francois Bisbo from Conference Call Oppenheimer. Your line is open. Speaker 600:20:39Hi, this is Dan. Sorry about that. Hi, this is Dan on for Frank. Thanks for taking my question. Regarding the P1C, You mentioned the 0.5 microgram per kilogram achieved the exposure levels similar to REMEDY-one. Speaker 600:20:55Of course, these are healthy volunteers, but Were there any PD parameters that were part of the data collected? Are you if you're able to share at this time if there was any dose response in the PKPD parameters in across the in across the 3 doses, any additional granularity you can share at this time on the P1C? Thanks. Speaker 100:21:24I think we've been having some troubles here with We lost Kirsten. Lost her here. Dan, no, I mean, this was these patients were healthy subjects. And I'll point out that the study design was quite similar to our Phase 1 trial we did in healthy subjects before launching our Phase 2 study for stroke. Speaker 600:21:48Thanks. Thanks for taking my questions. Speaker 500:21:53Thanks, Dan. Speaker 400:21:54Thank you. And seeing no further questions in queue at this time, I'll turn the call back over to our host. Speaker 100:22:02All right. Again, we'd like to thank everyone for joining us this morning and for your continued support. Our goal is to bring this important treatment to stroke patients asRead morePowered by